BACKGROUND: Significant controversy exists as to which treatment modality is most effective for small, solitary hepatocellular carcinomas (HCCs): radiofrequency ablation (RFA), surgical resection (RXN), or transplantation (TXP). Size cutoff values ranging from 20 to 50 mm have been proposed to achieve complete ablation. The current study compares outcomes between RFA, RXN, and TXP as first-line therapy for patients with HCC tumors measuring as large as 50 mm. METHODS: The Surveillance, Epidemiology, and End Results database was queried for patients with HCC tumors measuring up to 50 mm who were treated with RFA, RXN, or TXP between 2004 and 2013. Overall survival (OS) and disease-specific survival (DSS) were examined in patients with tumors measuring 20 mm, 21 to 30 mm, or 31 to 50 mm. The impact of an increase in tumor size of only 5 mm beyond 30 mm was evaluated by also examining outcomes in patients with tumors measuring 31 to 35 mm. RESULTS: Of 1894 cases, patients with HCC tumors measuring 20 mm and 21 to 30 mm demonstrated no difference in OS or DSS regardless of whether RFA and RXN was used. RFA was associated with a worse OS and DSS than TXP, whereas there was no difference in OS observed between RXN and TXP. In patients with tumors measuring 31 to 50 mm, OS and DSS were worse with RFA compared with RXN or TXP. Most important, the inferior DSS and OS noted with RFA were observed with only a 5-mm increase in tumors measuring >30 mm. CONCLUSIONS: Although RFA frequently is used as first-line treatment of HCC tumors measuring as large as 50 mm, it is associated with worse results than RXN or TXP for tumors measuring >30 mm. To the best of the authors' knowledge, the results of the current study are the first to demonstrate that although RFA is an appropriate option for patients with HCC tumors measuring 30 mm, its use for tumors even slightly larger than 30 mm is associated with inferior outcomes.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third leading cause of death worldwide. 1 In the United States, >15,000 men and 6000 women are diagnosed with primary liver cancer each year. 2 Liver transplantation (TXP) offers an excellent curative treatment option for patients with HCC, addressing both the underlying liver disease as well as the malignant process. 3 Unfortunately, because of a significant donor shortage, TXP is not a feasible option for the majority of patients. Furthermore, most patients with HCC are not candidates for curative surgical resection (RXN) at the time of diagnosis for various reasons, including extrahepatic metastasis, vascular invasion, high-risk anatomic location, large tumor size, large number of lesions, insufficient remnant liver to support life, or comorbid conditions. 4 Although techniques such as portal vein embolization have been developed to increase the chances of successful RXN, inadequate future liver remnant within the context of underlying liver disease and vascular invasion still represents a significant barrier to curative hepatectomy. 5, 6 Radiofrequency ablation (RFA) has been established as an acceptable and frequently used therapeutic option for patients with early HCC. 7 In some high-volume centers, especially in Asia, RFA is a first-line treatment option in patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 or stage A disease. 8 For patients with HCC who are candidates for both RFA and RXN, there is significant controversy with regard to which modality provides the best outcomes. Recent studies comparing RFA with RXN have demonstrated comparable outcomes and similar survival rates for RFA in patients with early-stage HCC (tumor size of 2-5 cm). [9] [10] [11] Although RFA can be successful as first-line therapy, the maximum HCC tumor size for which RFA is safe and effective remains highly controversial; size cutoff values of 20 mm, 30 mm, and 50 mm have been proposed. 9 Some authors have proposed a 20-mm cutoff value based on studies demonstrating that RXN results in longer survival than RFA in patients with poorly differentiated HCC measuring <20 mm. 12 A 30-mm cutoff value has been suggested by several authors and currently is recommended by the American Hepato-Pancreato-Biliary Association 13 and in the BCLC staging algorithm.
14 Despite concerns that RFA is ineffective for lesions measuring>30 mm, some reports have demonstrated that lesions measuring up to 50 mm can be ablated safely. 9, [15] [16] [17] In light of the controversy regarding the most effective first-line treatment strategy for patients with earlystage HCC, the objective of the current study was to compare the outcomes of RFA, RXN, and TXP among patients with HCC measuring up to 50 mm in a large epidemiological database and the impact of an increase in tumor size of only 5 mm beyond 30 mm on RFA outcomes.
MATERIALS AND METHODS

Patient Selection Criteria
The Surveillance, Epidemiology, and End Results (SEER) database was queried for patients with a histological diagnosis of HCC (International Classification of Diseases for Oncology, 3rd Edition [ICD-O-3] code 8170) between 2004 and 2013. Patients aged 18 years with known tumor size, tumor grade, number of tumors, intrahepatic vascular invasion status, fibrosis score, and metastatic disease status who were not diagnosed at autopsy were included in the current study. From that cohort, patients with a single tumor measuring 50 mm in size who underwent RFA, RXN, or TXP were chosen for comparison. The following SEER codes for liver and intrahepatic bile duct tumors (C220-C221) were selected: RFA: 16; RXN: 20 to 25, 30, 36, 37, 50, 51, and 52; and TXP: 61 and 66. Other forms of ablation were excluded because RFA is the only ablative modality with specific coding in the SEER database. Patients with incomplete survival data or a survival of <1 month were excluded from the current study.
Patient Grouping
Outcomes were analyzed for patients with tumors measuring 20 mm, 21 to 30 mm, 31 to 50 mm, or 31 to 35 mm. The 20-mm cutoff value was chosen on the basis of studies demonstrating longer survival and lower disease recurrence with RXN compared with RFA in patients with early-stage HCC measuring <20 mm. 12, 18 The 30-mm cutoff value was derived from published reports (including the current American Hepato-Pancreato-Biliary Association consensus statement) recommending RFA for tumors measuring <30 mm. 13 The cutoff value of 31 to 50 mm was chosen on the basis of reports that lesions measuring up to 50 mm can be ablated safely. 9, 15 The impact of a small incremental increase in size >30 mm was evaluated by examining outcomes in patients with tumors measuring 31 to 35 mm.
Outcome Measurement
The primary outcome was overall survival (OS), defined in SEER as time until death as a result of any cause. Disease-specific survival (DSS), defined as time until death attributed to HCC, was evaluated as a secondary outcome.
Statistical Analyses
The Kaplan-Meier method was used to analyze survival according to intervention for each tumor size group. Comparisons were performed using the log-rank test. Cox proportional hazards regression analysis was used to determine the simultaneous impact of potential confounders, including patient age and tumor size as continuous variables and patient sex, tumor grade, fibrosis score (none vs severe-cirrhosis), vascular invasion, and intervention as categorical variables. SEER database records fibrosis score as dichotomous variables (nonemoderate [score of 0-4] vs severe-cirrhosis [score of [5] [6] ). The actual score is not recorded, and for this reason fibrosis was included in the Cox proportional hazards regression model as a categorical variable. Statistical significance was set at the .05 level. R statistical software (R Foundation, Vienna, Austria) was used for all statistical analyses.
RESULTS
Of the 46,277 patients with a diagnosis of HCC in the SEER database during the examined time period, a total of 1894 met the criteria for data completeness. Baseline demographic and disease characteristics and treatment information are presented in Table 1 . The majority of Original Article patients (77%) were male. Tumors were most often grade 2. Patient age and sex and tumor vascular invasion and grade were distributed equally among the 4 tumor size groups. TXP was the most frequent intervention for patients with lesions measuring 20 mm; RFA, RXN, and TXP were distributed equally among patients with lesions measuring 21 to 30 mm; and RXN was the most frequent treatment modality for patients with tumors measuring 31 to 35 mm and 31 to 50 mm. The ratio of patients with severe fibrosis-cirrhosis was 81.2% in the RFA group, 54.1% in the RXN group, and 87.8% in the TXP group. The distribution of clinical characteristics is presented in Table 1 .
Overall Survival
The median follow-up was 29 months (10th and 90th percentiles were 5 months and 77 months, respectively). Kaplan-Meier survival analyses (Figs. 1A and 1B) were performed based on tumor size groups (20 mm, 21-30 mm, 31-50 mm, and 31-35 mm) and interventions within each group. OS was influenced by treatment modality within each tumor size group (Fig. 1) . The mean OS for patients with a tumor measuring 20 mm who underwent RFA was 60 months, whereas the OS times for those patients who underwent RXN or TXP were 70 months and 81 months, respectively. For the patients with tumors measuring 20 mm, RFA and RXN were associated with similar survival durations (P 5 .101), but the OS for TXP was significantly longer than that for RFA (P<.001). Outcomes for RXN and TXP were not found to be statistically significantly different (P 5 .118) ( Table 2) .
Similar results were found for tumors measuring 21 mm to 30 mm. For this group, the OS times for RFA and RXN were similar (P 5 .711), but that for TXP was significantly longer than that for RFA (P<.001). The mean OS for patients with a tumor measuring 21 to 30 mm who underwent RFA was 61 months, whereas the OS times for patients who underwent RXN or TXP were 70 months and 77 months, respectively. Similar to tumors measuring 20 mm, outcomes with RXN and TXP were not found to be statistically significantly different in tumors measuring 21 to 30 mm (P 5 .157) ( Table 2 ).
In contrast, for patients with tumors measuring 31 mm to 50 mm, RFA was found to be associated with worse OS than either RXN (P 5 .002) or TXP (P<.001). The median OS for patients with a tumor measuring 31 to 50 mm who underwent RFA was 49 months, whereas the OS times for patients who underwent RXN or TXP were 65 months and 77 months, respectively. In addition, TXP was found to be associated with longer survival than RXN in this group (P 5 .03).
It is important to note that an examination of outcomes for the subgroup of patients whose tumor measured 31 to 35 mm demonstrated that an incremental increase in tumor size of only 5 mm beyond 30 mm was associated with a worse outcome in patients who However, RFA appears to be an appropriate alternative for patients with HCC tumors measuring <3 cm, with outcomes comparable to those of surgical resection and ablation reported.
Adjustment for Confounding Factors and Factors Affecting OS and DSS
The relationship between treatment modality and outcome in each tumor size group remained largely unchanged after adjusting for other predictors of OS and DSS, including patient age and sex and tumor size, vascular invasion, presence of severe fibrosis-cirrhosis, and tumor grade (Tables 3 and 4 (Table 3 and Supplemental figure 1). Similar results were observed for tumors measuring 31 to 35 mm.
Disease-Specific Survival
Because OS in patients with HCC can be influenced by underlying liver disease, we used the endpoint of DSS in secondary analyses to isolate the influence of treatment intervention on cancer-specific outcomes. Results for DSS were similar to those for OS, with RFA demonstrating worse survival than RXN for patients with lesions measuring 31 to 50 mm, including those measuring 31 to 35 mm (Table 4) . For the patients with lesions measuring 20 mm, DSS was similar for those treated with RFA and RXN (P 5 .118). However, unlike OS, DSS was better for patients treated with TXP than for those treated with RFA (P<.001) or RXN (P<.001) ( Table 5 ).
In patients with tumors measuring 21 to 30 mm, the DSS of the RFA subgroup was similar to that of the RXN subgroup (P 5 .718), whereas TXP yielded significantly Finally, the examination of DSS for patients with tumors measuring 31 to 35 mm demonstrated that an increase in tumor size of only 5 mm beyond 30 mm was associated with worse outcomes in patients who underwent RFA compared with those who underwent RXN (P 5 .032). Again, DSS among patients in tumor size group was significantly better in the TXP subgroup than in the subgroups who underwent RFA (P 5 .007) or RXN (P 5 .034).
Adjustment for Confounding Factors Affecting DSS and Comparison of Treatment Modalities
The adjusted DSS in patients with a tumor measuring 20 mm who underwent RFA was not different from that of patients who underwent RXN (HR, 1.522; 95% CI, 0.976-2.374), and these can be considered comparable first-line treatment options (Table 4) . However, compared with the subgroup of patients who underwent TXP, the subgroup treated with RFA only (not RXN) had a higher rate of death (HR, 7.208; 95% CI, 3.102-16.750). For patients with lesions measuring 21 to 30 mm, DSS in the RFA subgroup was worse than that in the RXN subgroup (HR, 1.518; 95% CI, 1.008-2.033) and RXN can be considered to be a valid treatment option for patients with tumors in this size group. Similar to patients in the other tumor size groups, compared with patients in the TXP subgroup, patients in the RFA subgroup had a higher rate of death (HR, 3.549; 95% CI, 2.125-5.929). For patients with lesions measuring 31 to 50 mm, the adjusted DSS for patients who underwent RFA was poorer than that of patients who underwent RXN (HR, 1.835; 95% CI, 1.284-2.623) or TXP (HR, 6.102; 95% CI, 3.351-8.851). Similar results were observed for patients with tumors measuring 31 to 35 mm, indicating that a minor increase beyond 30 mm will lead to higher rates of death (Table 4) .
DISCUSSION
Liver TXP is the best treatment option with curative intent for patients with HCC. 19 Unfortunately, due to a shortage of available organs, RXN and RFA are more applicable techniques on a larger scale. Although RXN is considered to be a more efficient technique, the morbidity of laparotomy added to the risks of RXN in a diseased liver has been a limiting factor. 20 RFA increasingly is being used, especially in patients with significant underlying parenchymal disease, 21 and is considered the first-line treatment for patients with very early and early HCC (BCLC stages 0-A) who are not suitable for surgery. 22 In this population-based analysis, we sought to evaluate the relative efficacy of RFA, TXP, and RXN as firstline therapy for patients with early HCC. Furthermore, we aimed to determine whether there are differences in survival between RFA, TXP, and RXN when used as firstline therapy for patients with HCC tumors measuring >30 mm. The results from the current analysis confirm reports that RFA is an effective option for patients with HCC tumors measuring up to 30 mm in size. However, for patients with HCC tumors measuring >30 mm, even small increases in tumor size (5 mm) were found to result in significantly shorter survival for patients treated with RFA compared with those treated with RXN.
The findings of the current study are clinically highly relevant because the incidence of HCC is rising in the United States. Incidence rates of HCC in the United States historically have been lower than in other countries, particularly in Asia. However, in recent decades, ageadjusted incidence rates for HCC have doubled in the United States, and mortality rates for primary liver cancer have increased faster than those for any other leading cause of cancer.
2 Thus, the current study results demonstrating that RFA is an effective first-line option for patients with lesions measuring up to 30 mm is of clinical importance because HCC more and more often is diagnosed at this small size. This is due to increases in axial imaging in general, improved imaging technology, and the development of screening programs designed to detect small-size HCC tumors (formerly available only in highincidence countries).
3,10
The current study finding that RFA of tumors measuring >30 mm is associated with poorer outcome is particularly relevant because it has been proposed that HCC tumors measuring up to 50 mm can be ablated effectively. 9, 15 However, this has been a controversial topic because to the best of our knowledge a clear tumor size cutoff value for first-line treatment remains ill-defined. 23, 24 Studies with discrepant results regarding the efficacy of RFA for tumors of various sizes and the benefit of RFA compared with that of RXN or TXP have led to confusion. Tumors of patients undergoing RFA that are reported in the literature frequently measure >30 mm, and the results reported for these patients are conflicting. 9, 10, 25, 26 For example, a study from France that included 281 patients with HCC tumors measuring up to 50 mm demonstrated no difference in the 5-year survival rate between patients who underwent RFA and those who underwent RXN or TXP. 27 In addition, the results of a randomized controlled study of 168 patients with tumors measuring up to 40 mm and up to 2 nodules demonstrated no difference in the 3-year OS and recurrence-free survival rates. 28 Furthermore, in a study by Tohme et al, 9 110 patients were divided into groups whose HCC tumors measured <2 cm or between 2 and 5 cm. No differences in 5-year OS or disease-free survival were observed between the groups. Similarly, no survival difference was noted among patients with Child-Pugh class A cirrhosis who underwent RFA or RXN. 9 These data are discrepant from those of the current study indicating decreased survival for patients with lesions measuring >30 mm who are treated with RFA. However, even the size cutoff value of 30 mm has been questioned. A recently published study from Japan compared RFA with RXN in patients with small, poorly differentiated tumors: the maximum tumor size was 2 cm in the RFA group and 2.5 cm in the RXN group. RFA for these small tumors was found to be significantly inferior, demonstrating a cumulative 5-year survival rate of 32.7%, whereas RXN yielded a survival rate of 67.5%; the recurrence-free survival rate also was found to be significantly lower in the RFA group. 12 Furthermore, a Japanese nationwide survey of 12,968 patients with tumors measuring <3 cm found significantly lower odds of death and disease recurrence in patients who underwent RXN compared with those who underwent RFA. 29 Similarly, in a randomized controlled trial from China with 230 patients with HCC tumors conforming to Milan criteria, worse 5-year OS and recurrence-free survival as well as higher overall disease recurrence were noted in the RFA groups. 30 In a meta-analysis of 21,464 patients with early-stage HCC, patients treated with RXN were found to survive significantly longer compared with those treated with RFA. In that study, patients with a tumor measuring <3 cm who underwent RXN were found to have a significantly higher survival rate and longer disease-free survival than those who underwent RFA, whereas RFA was associated with fewer complications. 25 However, the results of the current study indicate that in Western surgical practice, RFA is an equally effective first-line treatment modality for HCC tumors measuring up to 30 mm if a precise size cutoff value is used. These results are consistent with reports from other Western series. 31 Gory et al recently published a study from Australia comparing RFA with RXN in 146 patients with HCC. For tumors measuring <3 cm, no difference in the median survival was found between patients treated with RFA and those treated with RXN (3-year survival rate of 66% vs 69%). However, when the patient cohort was extended to include individuals with tumors measuring >3 cm, a significant increase in local recurrence and lower recurrence-free and disease-free survival rates was observed in the RFA group. 10 These findings are consistent with the results of the current study.
The minimum ablative margin of RFA has been an area of discussion. To achieve a 1-cm ablative margin (A0), the maximum tumor size under optimal conditions (based on the standard kill zone from RFA of 5 cm) is 3 cm. Although some authors have proposed 0.5 cm as an adequate margin, an ablative negative margin of <1 cm has been shown to be associated with increased disease recurrence and worse OS. 32 Ke et al investigated 281 patients with a single HCC sized between 3 cm and 5 cm. Tumor recurrence and long-term survival were compared between patients who were treated with a 0.5-cm to 1-cm ablative margin (158 patients) and patients treated with an ablative margin >1 cm (123 patients). The patients treated with a margin 1 cm had a significantly lower survival rate, higher local tumor progression rate (70.9% vs 44.7%), and higher intrahepatic distal recurrence rate (45.6% vs 30.9%). 32 Worse outcomes observed with RFA in tumors measuring >30 mm appear to support the findings that ablative margins <1 cm are associated with a worse outcome and an increased rate of disease recurrence. Although RFA and RXN provide similar outcomes for patients with tumors measuring up to 3 cm, the data from the current study indicate that an increase of only 5 mm in HCC size (and subsequent reduction in the ablative margin) resulted in worse outcomes in the patients treated with RFA. This is highly relevant because in the current study, >25% of patients received RFA as first-line therapy for a lesion measuring 31 to 50 mm. The current study findings further demonstrate that TXP offered superior survival compared with RFA in all groups. RXN was similar to TXP in all patients with a tumor measuring up to 35 mm and remains a viable option for these individuals.
In a study by Silva et al, 105 patients with HCC with a single nodule measuring up to 5 cm on imaging underwent RXN. The 5-year survival rate in this cohort was 66% for patients treated with RXN versus 70% for those treated with TXP. 33 Although the authors reported similar 5-year survival rates in their series, another study by Sapisochin et al 34 reported the 5-year and 10-year survival and disease recurrence rates in 217 patients with HCC. A total of 95 patients with cirrhosis with HCC were treated with RXN whereas 122 patients underwent TXP. Although no difference was observed between TXP and RXN at 4 years, the 10-year survival rate was found to be worse in the RXN group (49% vs 33%; P 5 .002). The rate of disease recurrence also was found to be significantly higher in the RXN group (71.6%) compared with the TXP group (16%). More important, when the patients with tumors measuring <2 cm were examined separately, no difference in the 5-year and 10-year survival rates was observed (55% and 50% vs 62% and 50%, respectively; P 5.9). 34 The findings of the current study demonstrating similar survival for patients treated with RXN compared with those treated with TXP for tumors measuring up to 35 mm in size but worse outcomes with RXN for patients with tumors measuring 35 to 50 mm are in keeping with these results.
The current study has limitations specific to the SEER database. During the design of the study, we were limited by the reporting consistency of the SEER database. The database does not include comorbidity, underlying liver disease, tumor recurrence, number of ablation fields for RFA, or surgical margin status, all of which could have affected outcomes for any of the treatment approaches. Although data fields for international normalized ratio, creatinine, and bilirubin are present in the data structure, nearly none of the patients had this information entered. For that reason, the Child-Pugh score or Model For End-Stage Liver Disease (MELD) score could not be calculated reliably from SEER due to a lack of data. To provide the most accurate analyses possible with a registry of this size, we chose to include only those patients with complete data. This resulted in the exclusion of a significant number of patients for whom data were missing, and this affected the sample size of the RFA group due to the lack of data regarding fibrosis. However, we believed that the inclusion of fibrosis as a potential confounder is extremely important in patients with HCC. Indeed, fibrosis was found to be a significant factor affecting DSS and OS (Table 6 and 7) . Not correcting for the effect of fibrosis during comparison for treatment modalities would yield inaccurate results. Despite these exclusions, the sample size was still large enough to provide >15 patients per analyzed variable in the multivariable logistic regression analyses, which would provide significant analytical power. An additional limitation of the current study was the lack of information regarding portal hypertension and the actual fibrosis score. Although there were data available regarding the severity of fibrosis, this was recorded as either none-moderate (score of 0-4) or severe-cirrhosis. 5, 6 To compensate for this lack, we chose to analyze both OS and DSS when evaluating the treatment modalities. The goal was to include the burden of the underlying disease and the general condition of the patient in our analysis. Analyzing DSS only would provide information regarding the outcomes due to the malignant process, thereby ignoring the underlying liver disease. Conversely, analyzing OS indirectly incorporates the impact of the underlying liver disease and severe fibrosis. Furthermore, SEER was designed for cancer surveillance. The collected data pertaining to incidence, stage of disease, and survival assess first-line treatment only. Therefore, treatment sequencing could not be analyzed. Thus, the current study examined the effect of first-line treatment on survival only and did not compare sequential applications of liverdirected therapy regimens for patients with HCC.
In patients with early HCC, TXP would be the ideal treatment because the underlying disease process is addressed, not only the tumor. Despite the exception points assigned to patients with HCC, a shortage of donors continues to be the central issue. 35 The waiting time for liver TXP may reach 2 years in the United States, resulting in dropout rates of nearly 50% due to disease progression while patients are on the waiting list for TXP . 36, 37 For this reason, RFA is increasingly being used as either primary management of HCC or as a bridging therapy for TXP; the current study data validated RXN and RFA as reasonable bridging strategies. [32] [33] [34] This conclusion is based on data from the current study demonstrating that for patients with small lesions measuring <3 cm, RFA has DSS and OS rates similar to those for RXN and is an appropriate first-line treatment. However, even a small increase of 5 mm beyond 30 mm resulted in RFA being associated with an inferior outcome, and therefore RFA is considered inappropriate in patients with tumors measuring >30 mm; in these individuals, TXP or RXN should remain first-line therapy.
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